Upper Respiratory Tract infections during the first week of 2020 (Part II)

January 6, 2020 
Paul Herscu ND, MPH 
Herscu Laboratory

These three observations involving the current viral illnesses follow last week’s observation. Please read those first here: http://paulherscuepidemics.blogspot.com/2019/12/upper-respiratory-tract-infections.html

Upper Respiratory Tract infections during the last week of 2019

December 31, 2019
Paul Herscu ND, MPH
Herscu Laboratory

There are three specific observations I would like to make now, involving the current viral illnesses.

The first involves what is likely the common cold. Unlike the cold that I reported on a few years ago which led to numerous first time asthmatic crisis, in people who did not previously have asthma, this one seems to mostly present in the common fashion. What is unique about it though is how bad It is. The symptoms that we see are a runny nose, mostly with a bland clear discharge, a great deal of frontal sinus pressure, which leads to a congestive headache, extreme weakness, wiped out, exhausted, and some body aches. Low fever of 99-I00.5. In many ways, this is a slightly altered version of the remedy Gelsemium. My main comment here involves what happens after you take Gelsemium. Most often when you take the remedy at this time, the next day it appears as though ‘nothing happens’. You are still sick. And this is why I want to highlight an error here.

But first, as background, here are some numbers for what is typically found in the common cold, what the natural progression is:

1.     Fever can last up to 7-9 days.

2.     Sore throat can last up to 9 days

3.     Cough can last 2 weeks and even more.

4.     Runny nose can last 2 weeks and even more.

5.     The body aches can last 10 days to a couple of weeks.

Epidemic Update January 2019

January 22, 2019
Paul Herscu ND, MPH
Herscu Laboratory

Well, this is turning out to be an extremely busy winter season! There are several influenza-like-illnesses, as well as influenza, currently raging through the US and Europe. This is just a short update, building on many previous pieces written on this topic. I write here with an assumption that you understand the topic of the genus epidemicus (see Herscu Letters #33-38 to review the topic of the genus epidemicus,) the difference between acute and chronic prescribing at any given time in your patient, and of course that you know how to keep your patients safe. 

Currently, there are several common presentations:

Early Season Viral Infection Fall 2018

Part II: October 31, 2018
Paul Herscu ND, MPH
Herscu Laboratory

Dear all,

As we posted in early October, we are in the middle of an early season viral infection that is presenting in all aged patients. Much remains the same from our prior update but we are also seeing an additional remedy emerge. Below are the full details of what we are currently seeing, so that you do not need to refer back to the prior post. 

This information comes from what we’ve seen in our clinic to date, as well as what we’ve heard from colleagues from Asia and parts east, from where many of our flu strains arrive.

Early Season Viral Infection - October 8, 2018

Paul Herscu ND, MPH
Herscu Laboratory

Dear all,

In our usual habit of keeping our students, alumni, colleagues, and friends informed about current epidemics, we wanted to send a brief note.

As many of you have experienced in the clinic or in your homes, we are in the middle of an early season viral infection that is presenting in both children and adults. Here’s what we’ve seen so far:

Influenza Like Illness, Winter 2017-2018, Part 2

Influenza Like Illness, Winter 2017-2018

Part 2. January 4, 2018
Paul Herscu ND, MPH
Herscu Laboratory

A Country Divided

No. Not that way. I am describing the 2017-2018 viral season situation as it seems to be unfolding now. Early on, we saw many patients presenting needing Gelsemium, and then later in the season people presented with Lycopodium symptoms. And really, when looking at the end of 2017, it will be marked by a record number of patients presenting with Lycopodium symptoms and doing well with the remedy. In 36 years, I had never seen those sorts of numbers.

I will describe, briefly, where we are now. While many people are still presenting needing Lycopodium, there are a number of presentations now in different people, happening at the same time, which is where this title comes from. In North America, as well as Europe, there are several viruses happily infecting us, but also the weather is different than it was previously, and this combination has led to different presentations. And while we still follow all the rules described elsewhere on prescribing properly, including when to give the constitutional remedy as opposed to any of these listed, if the rules apply, here are remedies to think about.

Third Wave Prevention of Infectious Disease

Michael Norden MD
Paul Herscu ND, MPH
Herscu Laboratory

The rapid emergence of superbugs, resistant to essentially all drugs, threatens to return us to the horrors of the pre-antibiotic era, where countless people died from common infections. The answer to this crisis may eventually come from advances in biotechnology, which ironically helped create the problem to begin with, but until that day, we would like to propose an ancient approach as a potential answer. Here, I condense a 4-year conversation I have had with my friend Michael Norden MD, involving copper, which reflects part of my 40-year interest in this element. What follows are our thoughts on using copper as a passive yet potent antibacterial.

Some of the most exciting aspects of living in these times are the rapid discoveries occurring in science, related to our habitat in the natural world and especially on the cellular and subcellular level. As we are discovering more and more types of germs, we are having to come to terms with the implications of our discoveries. There are more types of germs than we ever imagined; the germs that surround us and are in us determine to a significant extent, our health. Regarding prevention, the concept of developing an individual vaccine for a specific germ soon becomes unwieldy, as it seems impractical to vaccinate ourselves against hundreds or thousands of potentially pathogenic bugs. Even the common influenza vaccine sometimes fails us. For example, this year, vaccine manufacturers predicted incorrectly and the vaccine developed appears to be only 10 to 20% effective. Regarding treatment, we have learned that we can not simply kill infectious agents, because germs adapt to become more virulent. The rapid and ubiquitous use of antimicrobials has led to superbugs threatening our therapeutic efficacy and creating dire challenges to our species. We often lose the battle with germs that perhaps we should not be fighting in the current manner in first place. Instead of active antimicrobial use, and instead of prevention solely by developing a specific vaccine for each germ, we may need to develop a third wave of thought, one focusing on passive antimicrobial coatings that do not create superbugs, which is where copper stands as one possibility. 

The EPA has now certified over 400 alloys as “antimicrobial copper.” Certification allows the claim of 99.9% of bacteria will be killed within 2 hours. Published studies show this efficacy against all types of pathologic microbes including resistant bacteria such as MRSA as well as many viruses and fungi. Microorganisms tested succumb to the copper effect.